MIRA Pharmaceuticals, Inc. MIRA 深 沪
已收盘 04-02 16:00:00 美东时间
1.11
+0.050
+4.72%
华盛通- 最 高1.12
- 今 开1.06
- 成交量 13.45万股
- 最 低 1.06
- 昨 收 1.06
- 总市值 4648.25万
- 52周最高 2.45
- 市盈率 静 --
- 换手率 0.32%
- 52周最低 0.83
- 委 比 -87.75%
- 总股本 4187.61万
- 历史最高 7.9799
- 量 比 0.64
- 振 幅 5.66%
- 历史最低 0.51
- 每 手 1
- 风险率 0.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多What's Going On With MIRA Pharma Stock Tuesday?
MIRA Pharmaceuticals (NASDAQ: MIRA) eyes IND submission for Mira-55 after new 2026 data confirms no CNS side effects.
03-24 21:22
MIRA Pharma Announces New Preclinical Data Demonstrating Mira-55 Did Not Produce Cannabinoid-Like CNS Side Effects Across Comprehensive Battery Of Validated Behavioral Assays
Previously shown to deliver morphine-comparable pain relief without opioid-related risks in a validated inflammatory pain model, supporting planned IND submission for inflammatory painMIAMI, FL / ACCESS Newswire / March
03-23 21:03
Mira Pharmaceuticals Completes Patient Dosing In Phase 1 Clinical Study Of Ketamir-2; No Serious Adverse Events, Dose-Limiting Toxicities Seen; Plans To File Phase 2a Clinical Trial, Supporting Documents To FDA In H1
https://www.sec.gov/ix?doc=/Archives/edgar/data/1904286/000149315226008707/form8-k.htm
03-04 05:33
MIRA Pharmaceuticals Initiated Dosing In Final Cohort of Its Phase 1 Multiple Ascending Dose Trial Of Ketamir-2; The Company Expects to Complete the Phase 1 Clinical Program by the End of Q1 of 2026
Phase 1 Progress and Phase 2a Development PlansThe ongoing randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, and pharmacokinetics of single and multiple oral
02-03 20:33
Mira Pharmaceuticals Q3 EPS $(1.18) Misses $(0.08) Estimate
Mira Pharmaceuticals (NASDAQ:MIRA) reported quarterly losses of $(1.18) per share which missed the analyst consensus estimate of $(0.08) by 1375 percent. This is a 742.86 percent decrease over losses of $(0.14) per share
2025-11-13 21:50
MIRA Pharmaceuticals Initiates The Multiple Ascending Dose Portion Of Its Ongoing Phase 1 Clinical Trial, Evaluating Its Lead Oral Candidate, Ketamir-2, In Healthy Volunteers; Advancing Toward Phase 2a Clinical Evaluation In Chemotherapy-Related Pain, A Condition With No Approved Treatments And Potential For FDA Fast Track Consideration
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company") announced that it has initiated the multiple ascending dose (MAD) portion of its ongoing Phase 1 clinical trial, evaluating its lead oral candidate,
2025-10-24 04:48
MIRA Pharmaceuticals Advances Ketamir-2 Clinical Trials
MIRA Pharmaceuticals, Inc. ( ($MIRA) ) has provided an update. MIRA Pharmaceuti...
2025-10-24 04:40
MIRA Pharmaceuticals Sells Shares at 66% Premium
The latest announcement is out from MIRA Pharmaceuticals, Inc. ( ($MIRA) ). On ...
2025-10-17 04:37
MIRA Pharmaceuticals Stock Surges Following Positive Preclinical Data
MIRA Pharmaceuticals shares are trading significantly higher on Thursday following the announcement of new preclinical data for its lead candidate Mira-55.
2025-10-17 02:16
Market-Moving News for October 16th
TSM: 2% | Taiwan Semiconductor Lifts Outlook After Blowout Quarter, CEO Says AI Signals From Clients Are 'Very Strong' JBHT: 14% | J.B. Hunt Transport Services shares are trading higher after the company
2025-10-16 19:14
